Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health/ and changes regularly. See the Directory of published versions
The ePI project aims primarily at European format of the SMPC, but the relationship with other projects is vital. Especially the USA and Japanese counterparts.
There has been a work on the mapping between the 3:
SmPC | JPI | USPI |
---|---|---|
1. Name of the medicinal product | beginning of document | beginning of document |
2. Qualitative and quantitative composition | 3.1 Composition | 11. Description + 3 dosage forms and strengths |
3. Pharmaceutical form | N/A | 11. Description |
4. Clinical particulars | - | - |
4.1 Therapeutic indications | 4. Indications | 1. Indications and usage |
4.2 Posology and method of administration | 6. Dosage and administration | 2. Dosage and administration |
4.3 Contraindications | 9. Precautions concerning patients with specific backgrounds | 4. Contraindications |
4.4 Special warnings and precautions for use | 9. Precautions concerning patients with specific backgrounds | 5. Warnings and precautions |
4.5 Interaction with other medicinal products and other forms of interaction | 10. Interactions | 7. Drug interactions |
4.6 Fertility, pregnancy and lactation | 9. Precautions concerning patients with specific backgrounds | 8. Use in specific populations |
4.7 Effects on ability to drive and use machines | 9.Precautions concerning patients with specific backgrounds | N/A |
4.8 Undesirable effects | 11. Adverse reactions | 6. Adverse reactions |
4.9 Overdose | 13. Overdosage | 10. Overdosage |
5. Pharmacological properties | - | - |
5.1 Pharmacodynamic properties | 18. Pharmacology | 12.1 Mechanism of Action + 12.2 Pharmacodynamics |
5.2 Pharmacokinetic properties | 16. Pharmacokinetics | 12.3 Pharmacokinetics |
5.3 Preclinical safety data | 17. Clinical studies | 14. Clinical studies |
6. Pharmaceutical particulars | - | - |
6.1 List of excipients | 3.1 Composition | N/A |
6.2 Incompatibilities | N/A | N/A |
6.3 Shelf life | beginning of document | N/A |
6.4 Special precautions for storage | beginning of document | 16. How supplied/storage and handling |
6.5 Nature and contents of container | N/A | 16. How supplied/storage and handling |
6.6 Special precautions for disposal and other handling | N/A | N/A |
7. Marketing authorisation holder | 26. Marketing authorization holder, etc. | N/A |
8. Marketing authorisation number(s) | 26. Marketing authorization holder, etc. | N/A |
9. Date of first authorisation/renewal of the authorisation | N/A | N/A |
10. Date of revision of the text | beginning of document | N/A |
The data for the SPL related IG is present here
So in terms of FHIR document, is also possible to create a mapping between sections in the Composition.
So..